Terlipressin Hrs denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits Terlipressin Quantities — and Why You Can Appeal

Terlipressin is an FDA-approved intravenous therapy for hepatorenal syndrome type 1 (HRS-1), typically administered in a hospital setting. Humana's quantity-limit policy caps the number of doses or the duration of the treatment course it will authorize in a single approval period. A quantity-limit denial means Humana acknowledges the drug may be appropriate but will not authorize more than its defined limit without additional clinical justification.

### Why This Denial Happens

Humana sets quantity limits based on the treatment course described in the FDA-approved prescribing information and its own coverage policy. For terlipressin, which is administered on a structured schedule, the limit is designed to correspond to the labeled course. When a patient's clinical course requires a duration or quantity outside that limit — for example, due to disease severity, slow response, or a complex hospital course — an automatic denial is generated.

### Why It's Appealable

Quantity limits are not clinically absolute. Federal appeal rights under ACA §2719 and ERISA §503 allow you to challenge any coverage limit that is being applied in a way that is clinically inappropriate for your specific situation. File the external-review request within approximately four months of the denial notice. For a patient who remains hospitalized with active HRS-1, the prescriber can request expedited review, with a decision due within 72 hours.

### Concrete Appeal Process

1. Request the policy — Ask Humana in writing for the specific quantity-limit criteria applied and the limit number. 2. Clinical exception request — Your treating physician should submit a written request for a quantity exception, explaining why the patient's clinical course requires the additional quantity. 3. Internal appeal — File within the deadline on the denial letter with the full documentation package below. 4. External review — Available after internal denial; an independent reviewer will assess whether the quantity limit is being applied in a clinically appropriate manner for this patient.

### Documentation to Gather

• Diagnosis confirmation — hepatologist or intensivist chart notes documenting HRS-1 and the current phase of treatment.
• Treatment-course documentation — records of doses already administered, with dates and the clinical response documented after each dose or interval.
• Clinical severity and trajectory — chart findings showing current organ function, response to treatment to date, and the treating physician's clinical rationale for continuing beyond the authorized quantity.
• Prescriber medical-necessity letter — the treating hepatologist or hospitalist should explain why the additional quantity is medically necessary given this patient's specific disease course, referencing the FDA-approved prescribing information and applicable professional society guidance (such as AASLD guidance on HRS management).

### Criteria-Mapping Structure

Obtain Humana's quantity-limit policy for terlipressin and the FDA prescribing label. In your appeal, create a table that shows: (1) the quantity already authorized and administered, (2) the clinical response at each point in treatment, and (3) the treating physician's documented rationale for the additional quantity requested. Linking the clinical trajectory directly to the quantity request — rather than simply asking for more — gives the reviewer a clear basis for approving the exception.